Drug intelligence / Profile preview

Saplingtan

Development stage: Unknown
Lead developer: Jacobson Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Saplingtan** is a Hong Kong over-the-counter analgesic and antipyretic brand. The registered core products, Saplingtan Tab and Saplingtan Powder, are fixed-dose oral combinations of **caffeine, ethenzamide, and paracetamol** used for temporary relief of mild-to-moderate pain and fever, including headache and toothache. Paracetamol and ethenzamide provide non-opioid analgesic and antipyretic activity, while caffeine is included as an analgesic adjuvant. The brand was acquired from Ling Chi Medicine Company by Jacobson in 2017; registered Saplingtan products are held and manufactured by Karen Pharmaceutical in Hong Kong.

Brand names: Saplingtan

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Saplingtan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saplingtan.

Explore the full profile